Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCVAC/PCa and ONCOS-102 in mCRPC
NCT03514836Phase 2Terminated
- Sponsor
- SOTIO Biotech
- Start
- May 2018
- Primary completion
- Jan 2021
- Modality
- Whole Cell Cancer Vaccines, Oncolytic Viruses, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of stapuldencel, ONCOS-102 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by SOTIO Biotech. Started May 2018; status: terminated.
02
Drugs
stapuldencelONCOS-102
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03514836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03514836.